{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"600"},{"groupId":"OG001","value":"800"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"The dose of pazopanib that is feasible when given in combination with radiation or chemoradiation in adult unresected intermediate- and high-risk NRSTS patients. Initially, up to 10 patients (minimum of 3 patients ≥ 2 and \\< 18 years of age and 3 patients ≥ 18 years of age) eligible for each of the two study cohorts were non-randomly assigned (to generate 8 patients evaluable for toxicity) to receive treatment with pazopanib at dose level 1. A protocol-defined list of pazopanib-associated adverse events were defined as dose-limiting toxicities. The pazopanib dose determined to be feasible was based on the number of patient-reported dose-limiting toxicities encountered.","groups":[{"description":"Dose-Finding CR: Chemoradiation plus pazopanib","id":"OG000","title":"All Adult Dose Finding CR Cohorts"},{"description":"Dose-Finding RT: Radiation therapy plus pazopanib","id":"OG001","title":"All Adult Dose Finding RT Cohorts"}],"paramType":"NUMBER","populationDescription":"Adult patients, excluding 1 ineligible patient in Dose-Finding RT group","reportingStatus":"POSTED","timeFrame":"After the first 6 weeks of Induction","title":"Feasible Dose: Adult","type":"PRIMARY","unitOfMeasure":"milligram"}